Pituitary Adenoma

Treat new or worsening lesion-specific symptoms as an escalation trigger. Visual symptoms, ocular motor deficits, severe acute headache with concern for hemorrhage, or other evidence of expanding sellar disease warrant urgent assessment by endocrinology, neurosurgery, and ophthalmology rather than interval imaging alone.Nature+2NaturePituitary incidentaloma: a Pituitary Society international consensus ...Wolters KluwerMacroprolactinomas and Nonfunctioning Pituitary... : Obstetrics & GynecologyWolters KluwerPITUITARY DISORDERS

Pregnancy does not eliminate compressive risk. In one series, symptomatic expansion occurred in 6 of 40 women with macroprolactinomas diagnosed before conception and in 1 of 7 women with nonfunctioning adenomas diagnosed before conception; two women had pituitary apoplexy. New headache or visual symptoms during pregnancy should therefore prompt assessment for expansion or apoplexy.Wolters KluwerWolters KluwerMacroprolactinomas and Nonfunctioning Pituitary... : Obstetrics & Gynecology

For a stable incidentally discovered sellar or parasellar lesion, individualize the urgency of endocrinology, neurosurgery, ophthalmology, dedicated pituitary imaging, pituitary hormone testing, and visual assessment according to lesion type, size, symptoms, and proximity to relevant structures.NatureNaturePituitary incidentaloma: a Pituitary Society international consensus ...

Obtain a focused baseline pituitary evaluation that can identify prolactin excess, GH excess, ACTH-dependent hypercortisolism, central thyroid dysfunction, gonadal-axis dysfunction, and impaired adrenal reserve. In patients with known pituitary tumor predisposition or symptomatic disease, surveillance panels include IGF-1, spot GH, prolactin, estradiol or testosterone, LH, FSH, TSH, free thyroxine, and morning cortisol; dynamic testing is used when needed to establish hormone excess or deficiency.PubMed+1PubMedAIP Familial Isolated Pituitary Adenomas - PubMedPubMedAIP Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf

An ACTH-driven hypercortisolism pathway requires biochemical confirmation of Cushing syndrome before localizing a pituitary source. Failure to suppress cortisol with physiologic dexamethasone testing supports Cushing syndrome; plasma ACTH then distinguishes ACTH-dependent disease from autonomous adrenal cortisol production, in which ACTH should be suppressed to less than 20 pg/mL.PubMedPubMedAbbreviated Tests of Endocrine Function - Clinical Methods - NCBI Bookshelf Current Cushing disease consensus guidance addresses diagnostic laboratory testing, imaging, treatment selection, complication management, and disease monitoring.ScienceDirectScienceDirectConsensus on diagnosis and management of Cushing's disease

Interpret a prolactin result with attention to competing causes of hyperprolactinemia and MRI correlation. A prolactin concentration of 30-200 ng/mL can reflect functional causes or microadenoma, and no provocative or suppressive biochemical test consistently distinguishes these possibilities; pituitary MRI is superior to CT for microadenoma detection, while CT has a high false-positive rate for lesions smaller than 6 mm.PubMedPubMedAbbreviated Tests of Endocrine Function - Clinical Methods - NCBI Bookshelf The prolactinoma consensus addresses biochemical assessment, imaging, disease-related complications, dopamine agonist withdrawal, surgery, radiation, pregnancy, chronic kidney disease, psychiatric disease, and other special situations.NatureNatureDiagnosis and management of prolactin-secreting pituitary adenomas

Discordant thyroid studies require biochemical interpretation before attributing an elevated TSH to primary hypothyroidism. Inappropriately elevated TSH with elevated free T4 and free T3 should prompt evaluation for central hyperthyroidism, including consideration of a TSH-secreting adenoma; one reported case incorporated alpha-subunit testing, alpha-subunit/TSH molar ratio, THRB testing, and pituitary assessment.endo2026 endocrineendo2026 endocrineENDO 2026

Obtain dedicated pituitary MRI to define a suspected adenoma and to distinguish a pituitary lesion from alternative sellar pathology. MRI is superior to CT for diagnosis of pituitary microadenoma; the benefit is greatest when a lesion is small or biochemical findings are equivocal.PubMedPubMedAbbreviated Tests of Endocrine Function - Clinical Methods - NCBI Bookshelf For incidentalomas, the need for dedicated imaging and visual assessment depends on whether the lesion is a macroadenoma, microadenoma, cystic lesion, or empty sella and on patient-specific clinical context.NatureNaturePituitary incidentaloma: a Pituitary Society international consensus ...

Visual assessment is not a formality in lesions with possible lesion-specific symptoms or anatomy threatening the visual apparatus. The incidentaloma consensus specifically identifies circumstances in which ophthalmology consultation and visual assessment are warranted, and recommends multidisciplinary review for new or deteriorating symptoms.NatureNaturePituitary incidentaloma: a Pituitary Society international consensus ...

Use pathology after resection to establish tumor lineage and guide the assessment of persistent, recurrent, or clinically aggressive disease. Aggressive pituitary adenomas are defined clinically by high recurrence and/or resistance to conventional therapies, rather than by a single histopathologic category; no biomarker is established as a complete early predictor of aggressive behavior.NatureNatureAggressive pituitary adenomas—diagnosis and emerging treatments | Nature Reviews Endocrinology

Transsphenoidal surgery is the principal local treatment for most clinically significant nonprolactin pituitary adenomas. Across functioning adenomas, treatment strategies are tailored by subtype and can include surgical resection, medical therapy, and/or radiation; transsphenoidal tumor resection is considered first-line treatment for acromegaly.Oxford Academic+1Oxford AcademicManagement of hormone-secreting pituitary adenomasuat ajnrPharmacological management of acromegaly: a current ... Cushing disease consensus guidance likewise places treatment selection within a diagnostic, complication-management, and longitudinal-monitoring framework.ScienceDirectScienceDirectConsensus on diagnosis and management of Cushing's disease

Prolactinoma is managed differently. Dopamine agonist therapy is a core medical treatment, and the contemporary consensus addresses efficacy, adverse effects, withdrawal, surgery, preoperative therapy, radiation, and special settings such as cystic, giant, aggressive, mixed GH/prolactin-secreting tumors and pregnancy.JAMA+1JAMADiagnosis and Treatment of Pituitary Adenomas: A ReviewNatureDiagnosis and management of prolactin-secreting pituitary adenomas Choose surgery or radiation through a multidisciplinary pathway when medical treatment is ineffective, not tolerated, or when local disease behavior requires additional control.NatureNatureDiagnosis and management of prolactin-secreting pituitary adenomas

For acromegaly with persistent disease after surgery or when surgery is not sufficient, medical options include somatostatin analogues, cabergoline, and pegvisomant.JAMAJAMADiagnosis and Treatment of Pituitary Adenomas: A Review Preoperative somatostatin analogue therapy has been evaluated specifically before transsphenoidal resection of GH-secreting adenomas, so its use should be individualized to operative and biochemical goals rather than presumed routine.Oxford AcademicOxford AcademicRole of Pharmacotherapy in Perioperative Management of ...

Reserve radiation as an adjunct for persistent or recurrent adenoma when durable local control is not achieved with surgery and subtype-appropriate medical therapy. Pituitary adenoma management requires balancing surgery, medical therapy, and radiation; radiation therapy sources describe doses of 20 Gy, but modality and dose selection require specialist planning.Oxford Academic+1Oxford AcademicRadiation Therapy in the Management of Pituitary AdenomasOxford AcademicSuccessful Volume Control of Invasive Pituitary Adenoma ...

After treatment, surveillance must be aligned with the tumor’s original hormonal phenotype and treatment modality. In symptomatic patients with AIP-associated familial isolated pituitary adenoma, annual clinical assessment and testing with IGF-1, spot GH, prolactin, estradiol or testosterone, LH, FSH, TSH, free thyroxine, and morning cortisol are recommended; MRI interval depends on clinical status, prior tumor extent, and treatment modality.PubMed+1PubMedAIP Familial Isolated Pituitary Adenomas - PubMedPubMedAIP Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf

Monitor complications caused by hormone excess, pituitary deficits, or treatment. In acromegaly, surveillance includes diabetes mellitus, hypertension, hypogonadism, osteoarthritis, and osteoporosis assessment; GeneReviews recommends colonoscopy beginning at age 40 years and repeating every 3-10 years according to colorectal lesions and IGF-1 levels in AIP-FIPA.PubMed+1PubMedAIP Familial Isolated Pituitary Adenomas - PubMedPubMedAIP Familial Isolated Pituitary Adenomas - GeneReviews® - NCBI Bookshelf

Use new biochemical activity, new visual symptoms, enlarging residual disease, recurrence after prior therapy, or intolerance/resistance to medical therapy as triggers for repeat multidisciplinary treatment planning. This is particularly important for tumors behaving aggressively, defined clinically by recurrence and/or resistance to conventional therapies.Nature+1NaturePituitary incidentaloma: a Pituitary Society international consensus ...NatureAggressive pituitary adenomas—diagnosis and emerging treatments | Nature Reviews Endocrinology